Login to Your Account



Clinic Roundup


Friday, March 29, 2013

• Biodel Inc., of Danbury, Conn., reported that enrollment has been completed in a Phase II study of its ultra-rapid-acting prandial insulin candidate BIOD-123. The study is evaluating the use of BIOD-123 vs. Humalog (insulin lispro, Eli Lilly and Co.) on measures of HbA1c, postprandial glucose excursions, glycemic variability, hypoglycemic event rates and weight changes in about 130 U.S. patients with Type 1 diabetes. Biodel expects to report top-line data from the trial in the third quarter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription